Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.

被引：0
|
作者：
Mai, Hai-Qiang [1 ]
Chen, Qiu-Yan [1 ]
Chen, Dongping [2 ]
Hu, Chaosu [3 ]
Yang, Kunyu [4 ]
Wen, Jiyu [5 ]
Li, Jingao [6 ]
Shi, Yingrui [7 ,8 ]
Jin, Feng [9 ]
Xu, Ruilian [10 ]
Pan, Jianji [11 ]
Qu, Shenhong [12 ]
Li, Ping [13 ]
Hu, Chunhong [14 ]
Liu, Yi-Chun [15 ]
Jiang, Yi [16 ]
He, Xia [17 ]
Wang, Hung-Ming [18 ]
Lim, Wan-Teck [19 ]
Xu, Rui-Hua [1 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[2] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China
[3] Fudan Univ, Ctr Canc, Shanghai, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[5] Affiliated Hosp Guangdong Med Univ, Zhanjiang, Peoples R China
[6] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China
[7] Xiangya Sch Med, Hunan Canc Hosp, Changsha, Peoples R China
[8] Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China
[9] Guizhou Med Univ, Guizhou Canc Hosp, Guiyang, Peoples R China
[10] Shenzhen Peoples Hosp, Shenzhen, Peoples R China
[11] Fujian Prov Canc Hosp, Fuzhou, Peoples R China
[12] Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China
[13] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[14] Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China
[15] Taichung Vet Gen Hosp, Taichung, Taiwan
[16] Canc Hosp Shantou Univ, Coll Med, Shantou, Peoples R China
[17] Jiangsu Canc Hosp, Nanjing, Peoples R China
[18] Chang Gung Mem Hosp, Taoyuan, Taiwan
[19] Natl Canc Ctr, Singapore, Singapore
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT226
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma
    Benson, Al B., III
    Wainberg, Zev A.
    Hecht, J. Randolph
    Vyushkov, Dmitry
    Dong, Hua
    Bendell, Johanna
    Kudrik, Fred
    ONCOLOGIST, 2017, 22 (03): : 241 - +
  • [22] Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study
    Valle, Juan W.
    Bai, Li-Yuan
    Orlova, Rashida
    Van Cutsem, Eric
    Alfonso, Jorge Adeva
    Chen, Li-Tzong
    Obermannova, Radka
    Ettrich, Thomas Jens
    Chen, Jen-Shi
    Wasan, Harpreet Singh
    Denlinger, Crystal S.
    Vogel, Arndt
    He, Aiwu Ruth
    Bousmans, Nathalie
    Girvan, Allicia C.
    Zhang, Wei
    Walgren, Richard A.
    Carlesi, Roberto
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [23] Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis
    Tian, Kun
    Han, Jiaqi
    Wang, Zhu
    Chen, Jie
    ORAL ONCOLOGY, 2022, 128
  • [24] Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC)
    Chen, Qiu-Yan
    Mai, Hai-Qiang
    Chen, Dong-Ping
    Hu, Chao-su
    Yang, Kunyu
    Wen, Jiyu
    Li, Jingao
    Shi, Yingrui
    Jin, Feng
    Xu, Ruilian
    Pan, Jian-ji
    Qu, Shenhong
    Li, Ping
    Hu, Chunhong
    Liu, Yi-Chun
    Jiang, Yi
    He, Xia
    Wang, Hung-Ming
    Lim, Darren Wan-Teck
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] KEYNOTE-826: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
    Shapira-Frommer, Ronnie
    Alexandre, Jerome
    Monk, Bradley
    Fehm, Tanja N.
    Colombo, Nicoletta
    Caceres, Maria V.
    Hasegawa, Kosei
    Dubot, Coraline
    Li, Jerry Jing
    Stein, Karen
    Keefe, Stephen Michael
    Tewari, Krishnansu Sujata
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] RATIONALE-309: Updated progresssion -free survival from a phase 3 double-blind trail of tislelizumab versus placebo, plus chemotherapy, as first -line treatment for recurrent/metastatic nasopharyngeal cancer.
    Zhang, Li
    Yang, Yunpeng
    Pan, Jian-Ji
    Chen, Xiaozhong
    Sun, Yan
    Wang, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36)
  • [27] Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial (vol 27, pg 1536, 2021)
    Mai, Hai-Qiang
    Chen, Qiu-Yan
    Chen, Dongping
    Hu, Chaosu
    Yang, Kunyu
    Wen, Jiyu
    Li, Jingao
    Shi, Ying-Rui
    Jin, Feng
    Xu, Ruilian
    Pan, Jianji
    Qu, Shenhong
    Li, Ping
    Hu, Chunhong
    Liu, Yi-Chun
    Jiang, Yi
    He, Xia
    Wang, Hung-Ming
    Lim, Wan-Teck
    Liao, Wangjun
    He, Xiaohui
    Chen, Xiaozhong
    Liu, Zhigang
    Yuan, Xianglin
    Li, Qi
    Lin, Xiaoyan
    Jing, Shanghua
    Chen, Yanju
    Lu, Yin
    Hsieh, Ching-Yun
    Yang, Muh-Hwa
    Yen, Chia-Jui
    Samol, Jens
    Feng, Hui
    Yao, Sheng
    Keegan, Patricia
    Xu, Rui-Hua
    NATURE MEDICINE, 2022, 28 (01) : 214 - 214
  • [28] KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC
    Cortes, J.
    Cescon, D. W.
    Rugo, H. S.
    Im, S-A.
    Yusof, M. Md
    Gallardo, C.
    Lipatov, O.
    Barrios, C. H.
    Perez-Garcia, J.
    Iwata, H.
    Masuda, N.
    Otero, M. Torregroza
    Gokmen, E.
    Loi, S.
    Guo, Z.
    Zhou, X.
    Karantza, V.
    Pan, W.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1289 - S1290
  • [29] Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial.
    Zhang, Li
    Yu, Gengsheng
    Jia, Jun
    Peng, Peijian
    Lin, Qing
    Xi, Xuping
    Peng, Jiewen
    Xu, Mingjun
    Chen, Dongping
    Lu, Xiaojun
    Wang, Rensheng
    Cao, Xiaolong
    Chen, Xiaozhong
    Lin, Zhixiong
    Xiong, Jian Ping
    Lin, Qin
    Xie, Conghua
    Li, Zhihua
    Zhao, Chong
    Hong, Shaodong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
    Fuchs, C. S.
    Azevedo, S.
    Okusaka, T.
    Van Laethem, J. -L.
    Lipton, L. R.
    Riess, H.
    Szczylik, C.
    Moore, M. J.
    Peeters, M.
    Bodoky, G.
    Ikeda, M.
    Melichar, B.
    Nemecek, R.
    Ohkawa, S.
    Swieboda-Sadlej, A.
    Tjulandin, S. A.
    Van Cutsem, E.
    Loberg, R.
    Haddad, V.
    Gansert, J. L.
    Bach, B. A.
    Carrato, A.
    ANNALS OF ONCOLOGY, 2015, 26 (05) : 921 - 927
12345